1 / 6

Terbium-161 vs Lutetium-177 Hope for Non-Responders

This presentation explores how Terbium-161 offers new hope for patients who do not respond well to Lutetium-177 therapy. With its superior energy emission profileu2014including Auger and conversion electronsu2014Tb-161 provides enhanced targeting of micrometastases, offering a potentially more effective option for difficult-to-treat prostate cancer cases.

Nuclearmedicinetherapy
Download Presentation

Terbium-161 vs Lutetium-177 Hope for Non-Responders

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nuclear Medicine Centre FMRi Gurugram INDIA Dr. Ishita B Sen Terbium-161 vs. Lutetium-177: Hope for Non-Responders www.nuclearmedicinetherapy.in

  2. Theoretical Benefits of Terbium-161 • Possibility of enhanced outcomes in: • Non-responders to Lu-177 • Partial responders or progressing patients • Terbium-161 has stronger cell-killing potential, including single cancer cells responsible for recurrence.

  3. Early Insights from Research • Preclinical studies suggest lower recurrence rates with Terbium • Auger electrons in Tb-161 allow deeper DNA damage, even in isolated cells • Indicates a potential upgrade in therapeutic precision over Lu-177

  4. The VIOLET Study • Major head-to-head clinical trial in Australia • Led by Prof. Michael Hofman • Comparing efficacy of Tb-161 vs. Lu-177 • Early results: Terbium shows superior response

  5. Future Implications • Terbium-161 may become a first-line therapy in future • Could replace Lutetium-177 for certain cancer types • More data and trials are needed before changing protocols Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

  6. For more information talk to Dr. Ishita B Sen today. dr.ishitasen@nuclearmedicinetherapy.in +91 8700 668 431 www.nuclearmedicinetherapy.in

More Related